广东药科大学学报第39卷transporters PepT1and PepT2[J].Nat Struct Mol Biol,2014,21(8):728-731.[16]NAGAMURA R,FUKUDA M,KAWAMOTO A,et al.Structuralbasis for oligomerization of the prokaryotic peptide transporter PepTSo2[J].Acta Crystallogr F Struct Biol Commun,2019,75(5): 348-358.[17]SOLCAN N,KWOK J,FOWLER P W,et al.Alternating accessmechanism in the POT family of oligopeptide transporters[J].EMBO J,2012,31(16):3411-3421.[18]HUANG C Y,OLIERIC V,MA P,et al.In meso in situ serialX-ray crystallography of soluble and membrane proteins[J].Acta Crystallogr D Biol Crystallogr,2015,71(6):1238-1256.[19]LYONS J A,PARKER J L,SOLCAN N,et al.Structural basis forpolyspecificity in the POT family of proton‐coupled oligopeptide transporters[J].EMBO Rep,2014,15(8):886-893.[20]HUANG C Y,OLIERIC V,MA P,et al.In meso in situ serialX-ray crystallography of soluble and membrane proteins at cryogenic temperatures[J].Acta Crystallogr D Struct Biol,2016,72(1):93-112.[21]MOLLEDO M M,QUISTGAARD E M,FLAYHAN A,et al.Multispecific substrate recognition in a proton-dependent oligopeptide transporter[J].Structure,2018,26(3):467-476. [22]MINHAS G S,BAWDON D,HERMAN R,et al.Structural basisof malodour precursor transport in the human axilla[J].Elife, 2018,7:e34995.[23]DOKI S,KATO H E,SOLCAN N,et al.Structural basis fordynamic mechanism of proton-coupled symport by the peptide transporter POT[J].Proc Natl Acad Sci,2013,110(28):11343-11348.[24]ZHAO Y,MAO G,LIU M,et al.Crystal structure of the E.colipeptide transporter YbgH[J].Structure,2014,22(8):1152-1160. [25]P ARKER J L,LI C,BRINTH A,et al.Proton movement and couplingin the POT family of peptide transporters[J].Proc Natl Acad Sci, 2017,114(50):13182-13187.[26]张强.利用小肠寡肽转运蛋白PEPT1提高喜树碱类化合物口服吸收的研究[D].哈尔滨:东北林业大学,2022.[27]TAMAI I,NAKANISHI T,NAKAHARA H,et al.Improvementof L‐dopa absorption by dipeptidyl derivation,utilizing peptide transporter PepT1[J].J Pharm Sci,1998,87(12):1542-1546. [28]HU M,SUBRAMANIAN P,MOSBERG H I,et e of thepeptide carrier system to improve the intestinal absorption of L-α-methyldopa:carrier kinetics,intestinal permeabilities,and in vitro hydrolysis of dipeptidyl derivatives of L-α-methyldopa[J].PharmRes,1989,6(1):66-70.[29]WANG H P,LU H H,LEE J S,et al.Intestinal absorption studieson peptide mimeticα-Methyldopa prodrugs[J].J Pharm Pharmacol, 1996,48(3):270-276.[30]孙勇兵,涂亮星,甘薇,等.在体单向肠灌流模型研究帕拉米韦拟肽类衍生物的大鼠小肠吸收特性[J].现代药物与临床,2018, 33(11):2763-2768.[31]SUN Y B,SUN J,SHI S,et al.Synthesis,transport and pharmacokineticsof5′-amino acid ester prodrugs of1-β-D-arabinofuranosylcytosine[J].Mol Pharm,2009,6(1):315-325.[32]ZHANG Y,SUN J,GAO Y,et al.A carrier-mediated prodrugapproach to improve the oral absorption of antileukemic drug decitabine[J].Mol Pharm,2013,10(8):3195-3202.[33]ANAND B S,NASHED Y E,MITRA A K.Novel dipeptideprodrugs of acyclovir for ocular herpes infections:Bioreversion, antiviral activity and transport across rabbit cornea[J].Curr Eye Res,2003,26(3/4):151-163.[34]EZRA A,HOFFMAN A,BREUER E,et al.A peptide prodrugapproach for improving bisphosphonate oral absorption[J].J Med Chem,2000,43(20):3641-3652.[35]ANAND B S,KATRAGADDA S,MITRA A K.Pharmacokineticsof novel dipeptide ester prodrugs of acyclovir after oral adminis‐tration:intestinal absorption and liver metabolism[J].J Pharmacol Exp Ther,2004,311(2):659-667.[36]周洁.基于PEPT1载体蛋白进行前药设计的探索性研究[D].上海:上海交通大学,2009.[37]孙进.药物转运体[M].北京:人民卫生出版社,2019.[38]VIG B,RAUTIO J.Amino acid prodrugs for oral delivery:challenges and opportunities[J].Ther Deliv,2011,2(8):959-962. [39]PIERRA C,AMADOR A,BENZARIA S,et al.Synthesis andpharmacokinetics of valopicitabine(NM283),an efficient prodrug of the potent anti-HCV agent2'-C-methylcytidine[J].J Med Chem,2006,49(22):6614-6620.[40]DOUSSON C B.Current and future use of nucleo(s)tideprodrugs in the treatment of hepatitis C virus infection[J].Antivir Chem Chemother,2018,26:2040206618756430.[41]THOMPSON B R,SHI J,ZHU H J,et al.Pharmacokinetics ofgemcitabine and its amino acid ester prodrug following intravenous and oral administrations in mice[J].Biochem Pharmacol,2020, 180(9):114127.（责任编辑：陈翔）美国FDA批准首种纳洛酮鼻腔喷剂非处方药美国FDA于2023年3月29日批准一种非处方药类型纳洛酮鼻腔喷剂Narcan（4mg盐酸纳洛酮鼻腔喷剂）。
